VRDN-003
Thyroid Eye Disease (TED)
Phase 1/2Active
Key Facts
About Viridian Therapeutics
Viridian Therapeutics is a clinical-stage biotech focused on developing novel antibody therapeutics for rare autoimmune conditions, most notably Thyroid Eye Disease (TED). The company's strategy is built on a proprietary antibody engineering platform targeting the neonatal Fc receptor (FcRn) to reduce pathogenic autoantibodies. Its lead programs, VRDN-001 and VRDN-003, are in late-stage development for TED, positioning Viridian as a key player in a market with limited treatment options. The company aims to deliver optimized therapies with potential advantages in dosing, efficacy, and safety.
View full company profileTherapeutic Areas
Other Thyroid Eye Disease (TED) Drugs
| Drug | Company | Phase |
|---|---|---|
| Oral K9 | Inflammasome Therapeutics | Phase I |
| LASN01 | Lassen Therapeutics | Phase 1 |
| Batoclimab | Immunovant | Phase 3 |
| IMVT-1402 | Immunovant | Phase 2 |
| VRDN-001 | Viridian Therapeutics | Phase 3 |